LONDON, Jan. 13, 2020 /PRNewswire/ -- COMPASS Pathways, a mental health care company, announced today that it has been granted US Patent No 10,519,175, relating to methods of treating drug-resistant ...

LONDON, Jan. 13, 2020 /CNW/ -- COMPASS Pathways, a mental health care company, announced today that it has been granted US Patent No 10,519,175, relating to methods of treating drug-resistant ...

TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of ...

After more than a decade of treating patients whose depression or PTSD did not fully resolve on standard antidepressants — ...

Dosages for the Phase IIa programme were selected following the successful completion of the double-blind stage of Beckley Psytech’s Phase I study earlier this year, which showed that BPL-003 was well ...

MUNICH, Germany, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Ketabon GmbH (“Ketabon” or “the Company”), a joint venture between HMNC Brain Health and Develco Pharma, announced today favorable results from its ...

The FDA designation expands the drug's potential patient pool tenfold, to an estimated 13 million Americans who consider suicide annually. Clinical trials demonstrated rapid and statistically ...